Welcome to our dedicated page for HIGHCAPE CAPITAL news (Ticker: CAPA), a resource for investors and traders seeking the latest updates and insights on HIGHCAPE CAPITAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HIGHCAPE CAPITAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HIGHCAPE CAPITAL's position in the market.
Quantum-Si (NASDAQ: QSI) has expanded its Platinum early access program to ten global sites, including notable academic centers and industry partners. This initiative aims to enhance understanding of the proteome, which currently sees only 2% of its estimated million protein structures analyzed. The program supports the development of multi-omic assays and advanced biomarker characterization, positioning Quantum-Si to address critical biological research needs. CEO John Stark emphasizes the company's momentum in transforming proteomics and advancing drug discovery.
Quantum-Si Incorporated (NASDAQ: QSI) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO John Stark and CFO Claudia Drayton will host a virtual fireside chat on September 29 from 1:20 to 1:50 PM EDT. Quantum-Si is focused on advancing proteomics through a novel semiconductor chip enabling next-generation protein sequencing. For more details, visit the Investor Relations section on their website.
Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si aims to transform drug discovery and diagnostics.
Quantum-Si (Nasdaq: QSI) announced its second-quarter 2021 financial results, highlighting a net loss of $35.7 million, up from a loss of $8.2 million in Q2 2020. Operating expenses surged to $32.2 million, a 292% increase year-over-year. Positive developments included the completion of a business combination with HighCape, adding over $511 million in cash, and the delivery of five early access systems to key thought leaders in the proteomics field. The company plans to build a 25,000 square foot facility in San Diego to enhance R&D and production capabilities.
Quantum-Si announced the rescheduling of its second quarter 2021 financial results conference call to August 16, 2021, post-market close. CEO John Stark and CFO Claudia Drayton will host the call at 4:30 p.m. ET to discuss financial results and a business update. The call will be available via webcast on the Investor Relations website. Quantum-Si, founded in 2013, focuses on semiconductor chip-based proteomics, leveraging technology aimed at advancing drug discovery and diagnostics beyond DNA sequencing.
Quantum-Si Incorporated has signed a lease with Phase 3 Real Estate Partners for a 25,586-square-foot facility in San Diego, CA. This site will enhance its product development and R&D capabilities, crucial for recruiting talent and commercial readiness in the proteomics market. Operations are anticipated to commence in Q3 2021. CEO John Stark emphasized the facility's role in scaling operations to meet the growing demand for protein sequencing technologies, which are expected to revolutionize drug discovery and diagnostics.
Quantum-Si Incorporated (Nasdaq: QSI) has successfully completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), resulting in over $500 million for the development of its semiconductor chip-based protein sequencing technology. The combined company, now trading as Quantum-Si, aims to disrupt the $21 billion academic research and drug discovery market with its unique end-to-end solution. The company’s leadership includes experienced executives and it anticipates launching its products commercially in 2022.
HighCape Capital Acquisition Corp. (Nasdaq: CAPA) announces a virtual special meeting on June 9, 2021, for stockholders to vote on a proposed business combination with Quantum-Si, a cutting-edge company focused on semiconductor chip-based proteomics. The meeting will require a majority vote for approval of the combination and related proposals. HighCape encourages stockholders to vote by proxy to ensure representation. Quantum-Si aims to advance drug discovery and diagnostics through innovative technology. The combined company is expected to trade under the symbol 'QSI' post-transaction.
HighCape Capital Acquisition Corp. (Nasdaq: CAPA) is calling on its shareholders to vote in the special meeting scheduled for June 9, 2021, regarding its proposed business combination with Quantum-Si Incorporated, a company innovating in semiconductor chip-based proteomics. Approval requires a majority vote from HighCape stockholders. Shareholders can vote via mail, internet, or phone. Quantum-Si aims to enhance proteomic research and drug discovery, with plans for its shares to trade under the symbol 'QSI' post-combination.
HighCape Capital Acquisition Corp. announced a special meeting on June 9, 2021, for stockholder approval of its proposed business combination with Quantum-Si. The SEC has declared the Registration Statement on Form S-4 effective, facilitating the merger process. HighCape will mail the definitive proxy statement/prospectus to stockholders, who are encouraged to review the important details regarding the business combination. Quantum-Si aims to innovate in proteomics through its semiconductor chip technology, enhancing drug discovery and diagnostics.
Quantum-Si Incorporated has announced the appointment of Marijn Dekkers, Ph.D. and Ruth Fattori to its Board of Directors. They will remain on the board following the merger with HighCape Capital Acquisition Corp (Nasdaq: CAPA). Dr. Dekkers and Ms. Fattori bring extensive experience from leading roles at Bayer, Thermo Fisher Scientific, and PepsiCo. Their expertise is expected to enhance Quantum-Si's position in next-generation protein sequencing, which aims to revolutionize drug discovery and diagnostics.
